Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Ovarian Adenocarcinoma
CPT-11 and mitomycin C treated ovarian clear cell adenocarcinoma
August 18th, 2005
Irinotecan hydrochloride (CPT-11) and mitomycin C (MMC) were used as the first line chemotherapy for ovarian clear cell adenocarcinoma (OCCA). "The purpose of this study was to report the results of adjuvant CPT-11 and MMC combination chemotherapy (CPT-M) for OCCA. Between 1996 and 2002, 20 patients with OCCA underwent primary debulking surgery and received 6 treatments of CPT-11 (140 mg/m2) in combination with MMC (7 mg/m2), 2 weeks apart with a space of 3-4 weeks between the 3rd and 4th treatment in adjuvant setting," scientists in Japan reported. "Overall survival was compared with our historical control treated between 1983...
Source: Women's Health Weekly (2005-08-18)
|
